Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Accured Expenses (2018 - 2025)

UroGen Pharma's Change in Accured Expenses history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 532.79% year-over-year to $1.1 million; the TTM value through Dec 2025 reached -$202000.0, up 17.21%, while the annual FY2025 figure was -$202000.0, 17.21% up from the prior year.
  • Change in Accured Expenses reached $1.1 million in Q4 2025 per URGN's latest filing, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q2 2021 to a low of -$6.3 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $72842.1, with a median of -$184000.0 recorded in 2022.
  • The largest YoY upside for Change in Accured Expenses was 877.72% in 2023 against a maximum downside of 590.48% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.0 million in 2021, then skyrocketed by 148.98% to $985000.0 in 2022, then soared by 332.49% to $4.3 million in 2023, then crashed by 105.73% to -$244000.0 in 2024, then soared by 532.79% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Change in Accured Expenses are $1.1 million (Q4 2025), -$1.3 million (Q3 2025), and $3.7 million (Q2 2025).